Table 1.
Patient demographics
| Chronic rejection (N = 39) | Comparator (N = 39) | p-Value | |
|---|---|---|---|
| Age1 | 43 | 45 | NS |
| Male sex | 70% | 69% | NS |
| Race | |||
| White | 79% | 92% | NS |
| Hispanic | 5% | 3% | |
| AA | 15% | 3% | |
| Other | 1% | 3% | |
| Donor age1 | 29 | 20 | NS |
| MELD at OLT1 | 17 | 17 | NS |
| Cold ischemia time1 | 7.8 | 9.3 | NS |
| Year OLT1 | 1991 | 1994 | NS |
| Month 1 immunosuppression | |||
| Tacrolimus | 28% | 28% | NS |
| Cyclosporine | 72% | 72% | |
| Steroids | 94% | 92% | NS |
| MMF | 17% | 5% | NS |
| Azathioprine | 25% | 26% | |
| Cytomegalovirus | 49% | 21% | p = 0.02 |
| Primary liver disease | |||
| PSC | 14 | 10 | NS |
| Cryptogenic | 7 | 6 | |
| Alcoholic liver disease | 5 | 9 | |
| Acute liver failure | 5 | 1 | |
| Autoimmune hepatitis | 1 | 0 | |
| Metabolic/congenital | 4 | 4 | |
| HBV/SVR HCV | 1 | 5 | |
| Other | 2 | 4 | |
| Graft survival (months)1 | 15 | 159 | p < 0.001 |
| Alive | 20% | 69% | p < 0.001 |
| Re-OLT | 74% | 0 | p < 0.001 |
| Acute cellular rejection | |||
| 0 | 13% | 100% | p < 0.001 |
| 1 | 18% | ||
| 2 | 15% | ||
| ≥3 | 54% | ||
| Steroid resistant rejection | |||
| 0 | 56% | 100% | p < 0.001 |
| ≥1 | 44% | 0% | |
1
Median values.
AA, African American; MELD, model for end-stage liver disease; OLT, orthotopic liver transplant; PSC, primary sclerosing cholangitis; MMF, mycophenolate mofetil; HBV, hepatitis B; SVR HCV, sustained virologic response to hepatitis C (patients were only included if this occurred pre-OLT).